Functional reassessment of P16 variants using a transfection-based assay

International Journal of Cancer

Volumn 82, Issue 2, 1999, Pages 305-312

  Walker, Graeme J ^a   Gabrielli, Brian G ^a   Castellano, Marina ^a   Hayward, Nicholas K ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ARTICLE; CANCER SUSCEPTIBILITY; CHROMOSOME 9P; CONTROLLED STUDY; GENE DELETION; GENE LOCATION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL;

CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOPLASM; DNA, COMPLEMENTARY; DNA, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE DELETION; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; MUTATION; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; VARIATION (GENETICS);

EID: 0033013780     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990719)82:2<305::AID-IJC24>3.0.CO;2-Z     Document Type: Article

References (37)

1. APRELIKOVA O., XIONG, Y., and LIU, E.T., Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block phosphorylation of the cyclin-dependent kinases by CDK-activating kinase. J. biol. Chem., 270, 18195-18197 (1995).
2. CAIRNS, P. and 19 OTHERS, Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature (Genet.), 11, 210-212 (1995).
3. CASTELLANO, M., GABRIELLI, B.G., HUSSUSSIAN, C.J., DRACOPOLI, N.C. and HAYWARD, N.K., Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. J. Invest. Dermatol., 109, 61-68 (1997a).
4. CASTELLANO, M., POLLOCK, P.M., WALTERS, M.K., SPARROW, L.E., DOWN, L.M., GABRIELLI, B.G., PARSONS, P.G. and HAYWARD, N.K., CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res., 57, 4868-4875 (1997b).
5. 1 cell cycle-regulatory pathway in neuroblastoma. Int. J. Cancer, 80, 145-154 (1998).
6. EMIG, R., MAGENER, A., EHEMANN, V., V., MEYER, A., STILGENBAUER, F., VOLKMANN, M., WALLWIENER, D. and SINN, H-P., Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Brit. J. Cancer, 78, 1661-1668 (1998).
7. FLORES, J.F., POLLOCK, P.M., WALKER, G.J., GLENDENING, J.M., LIN, A., PALMER, J.M., WALTERS, M.K., HAYWARD, N.K. and FOUNTAIN, J.W., Analysis of CDKN2A, CDKN2B, and CDK4 genes in 49 Australian melanoma kindreds. Oncogens, 15, 2000-3005 (1997).
8. HAYWARD, N.K., The current situation with regard to human melanoma and genetic inferences. Curr. Opin. Oncol., 8, 136-142 (1996).
9. HUSSUSSIAN, C.J., STRUEWING, J.P., GOLDSTEIN, A.M., HIGGINS, P.A.T., ALLY, D.S., SHEAHAN, M.D., CLARK JR., W.H., TUCKER, M.A. and DRACOPOLI, N.C., Germline p16 mutations in familial melanoma. Nature (Genet), 8, 15-21 (1994).
10. KAMB, A., GRUIS, N.A., WEAVER-FELDHAUS, J., LIU, Q., HARSHMAN, K., TAVTIGIAN, S.V., STOCKERT, E., DAY III, R.S., JOHNSON, B.E. and SKOLNICK, M.H., A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440 (1994a).
11. KAMB, A., SHATTUCK-EIDENS, D., ECLES, R., LIU, Q., GRUIS, N.A., ET AL., Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature (Genet), 8, 23-26 (1994b).
12. KOH, J., ENDERS, G.H., DYNLACHT, B.D. and HARLOW, E., Tumor-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature, 375, 506-510 (1995).
13. INK4a) gene in microdissected sporadic primary melanomas. Int. J. Cancer, 75, 193-198 (1998).
14. LAMPHERE, L., FIORE, F., XU, X., BRIZUELA, L., KEEZER, S., SARDET, C., DRAETTA, G.F. and GYURIS, J., Interaction between Cdc37 and Cdk4 in human cells. Oncogene, 14, 1999-2004 (1997).
15. INK4 CDK inhibitory activity. Int. J. Cancer, 66, 249-254 (1996).
16. LIU, Q., NEUHAUSEN, S., MCCLURE, M., FRYE, C., WEAVER-FELDHAUS, J., GRUIS, N.A., EDDINGTON, K., ALLALUNIS-TURNER, M.J., SKOLNICK, M.H., FUJIMURA, F.K. and KAMB, A., CDKN2A (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10, 1061-1067 (1995).
17. LUKAS, J., PARRY, D., AAGAARD, L., MANN, D.J., BARTKOVA, J., STRAUSS, M., PETERS, G. and BARTEK, J., Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature (Lond.), 375, 503-510 (1995).
18. MONZON, J., LIU, L., GOLDSTEIN, A.M., TUCKER, M.A., FROM, L., MCLAUGHLIN, J., HOGG, D. and LASSAM, N.J., CDKN2A mutations in multiple primary melanomas. N. Engl. J. Med., 338, 879-887 (1998).
19. NOBORI, T., MIURA, K., WU, D.J., LOIS, A., TAKABAYASHI, K. and CARSON, D. A., Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond. ), 368, 753-756 (1994).
20. INK4 in human cancer. Proc. nat. Acad. Sci. (Wash.), 19, 11045-11049 (1994).
21. PARRY, D. and PETERS, G., Temperature sensitive mutants of p16/CDKN2 associated with familial melanoma. Mol. Cell Biol., 16, 3844-3852 (1996).
22. POLLOCK, P.M., PEARSON, J.V. and HAYWARD, N.K., Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer, 15, 77-88 (1996).
23. POLLOCK, P.M. and 12 OTHERS, Haplotype analysis of 2 recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum. Mutation, 11, 424-431 (1998).
24. POLLOCK, P.M., YU, F., QIU, L., PARSONS, P.G., and HAYWARD, N.K., Evidence of UV induction of CDKN2 mutations in melanoma cell lines. Oncogene, 11, 663-668 (1995).
25. ink4 function. Nature (Genet.), 10, 114-116 (1995).
26. REYMOND, A. and BRENT, R., p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene, 11, 1173-1178 (1995).
27. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Develop., 11, 492-503 (1997).
28. INK4a. Nature (Lond.), 395, 237-243 (1998).
29. SERRANO, M., HANNON, G.J. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366, 704-707 (1993).
30. CDC37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilises CDK4. Genes Develop., 10, 1491 (1996).
31. SUN, S., LIU, L., KARIMI, S., JOTHY, S., MILNER, B.J., RENWICK, A., LASSAM, N.J., HAYWARD, N.K., HOGG, D., NAROD, S.A. and FOULKES, W.D., CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int. J. Cancer, 73, 531-536 (1997).
32. TASSAN, J.P., SCHULTZ, S.J., BARTEK, J. and NIGG, E.A., Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J. Cell Biol., 127, 467-478 (1994).
33. INK4 gene in Australian melanoma kindreds. Hum. mol. Genet., 4, 1845-1852 (1995).
34. 2 phase cell cycle delay. Cancer Res., 56, 2510-2514 (1996).
35. WICK, S., DUBAY, M.M., IMANIL, I. and BRIZUELA, L., Biochemical and mutagenic analysis of the melanoma tumour suppressor gene product/p16. Oncogene, 11, 2013-2019 (1995).
36. Ink4a tumor suppressor protein. Cancer Res., 55, 2503-2506 (1995).
37. INK4 proteins encoded by tumour-derived alleles. J. biol. Chem., 271, 28734-28737 (1996).